News | July 30, 2025
Merck unveils $3 billion cost cutting plan
The savings will be fully reinvested to support new product launches and its pipeline across multiple therapeutic areas
The savings will be fully reinvested to support new product launches and its pipeline across multiple therapeutic areas
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population
FDA requests Sarepta Therapeutics to suspend distribution of Elevidys and places clinical trials on hold for multiple gene therapy products following 3 deaths
Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials
Capricor’s BLA for Deramiocel received Priority Review in March 2025
Spikevax is now approved for all individuals aged 6 months through 64 years at increased risk for COVID-19 disease
He has held senior leadership positions at Syngene International, Fujifilm Diosynth Biotechnologies, Thermo Fisher Scientific, Sartorius Stedim Biotech, and other leading organizations
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
Subscribe To Our Newsletter & Stay Updated
